Wiley launches AI-powered literature search tool on AWS

HOBOKEN, N.J. - Wiley (NYSE: WLY), a global leader in research and education publishing with a market capitalization of $2.4 billion and an impressive 31-year track record of consistent dividend payments, has announced a collaboration with Amazon Web Services (AWS) to introduce an advanced AI agent designed to enhance scientific literature searches. The tool will debut at the AWS Life Sciences Symposium in New York City on Tuesday. According to InvestingPro data, Wiley maintains a robust gross profit margin of 76%, demonstrating its operational efficiency in the publishing sector.

The AI agent, a first from a publisher on AWS, will enable comprehensive searches across Wiley’s extensive journal content, allowing researchers to delve into full-text articles, including detailed sections like methods and results. This marks a significant leap from the traditional abstract-only searches, aiming to streamline the research process by providing quick access to reliable and cited information.

Part of an open-source toolkit for healthcare and life sciences developed by AWS, the AI agent is intended to assist a range of use cases, from biomarker discovery to clinical trial protocol generation. At launch, it will offer AI searchable access to articles under the creative commons license, including journals like Cancer Medicine.

Josh Jarrett, SVP and GM of AI Growth at Wiley, emphasized the potential of integrating comprehensive literature search into researchers’ workflows to accelerate innovation. Dan Sheeran, General Manager of Healthcare and Life Sciences at AWS, echoed this sentiment, highlighting the importance of AI-powered agents in enriching evidence-based research with dynamic and verifiable scientific content.

Wiley’s development of this AI agent underscores the company’s dedication to innovative AI solutions while adhering to responsible AI practices, focusing on human oversight, transparency, fairness, and proper governance.

Life sciences professionals attending the AWS Life Sciences Symposium will have the opportunity to learn more about this collaborative effort.

This initiative represents Wiley’s ongoing commitment to empowering knowledge-seekers and supporting the life sciences community’s efforts to build more informed discovery systems. The company’s financial health appears stable, with analysts expecting net income growth this year. With a current dividend yield of 3.2% and a 26-year history of consecutive dividend increases, Wiley continues to reward long-term shareholders. The information for this article is based on a press release statement.For deeper insights into Wiley’s financial performance and access to additional InvestingPro Tips, including detailed analysis of the company’s valuation metrics and growth prospects, subscribers can access the comprehensive Pro Research Report, part of the extensive coverage available for over 1,400 US stocks.

In other recent news, John Wiley & Sons reported its first-quarter 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.84, above the forecast of $0.65. The company’s revenue reached $405 million, exceeding the anticipated $401.1 million, highlighting Wiley’s effective cost management and strategic initiatives. Wiley also reaffirmed its fiscal 2025 revenue guidance of $1.65-$1.69 billion and raised its fiscal 2026 margin target to above 25%. In addition, the company announced a slight increase in its quarterly cash dividend to $0.3525 per share, reflecting a modest annual increase from $1.40 to $1.41 per share. Wiley’s Board of Directors expressed confidence in the company’s financial health, marking the 31st consecutive year of dividend increases. Furthermore, Wiley disclosed an update to the compensation arrangement for its Interim CFO, Christopher Caridi, with an increase in his annual base salary and a higher performance-based cash bonus eligibility. These developments underscore Wiley’s strategic focus and strong financial performance amidst a challenging environment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.